Skip to main content
Journal ArticleOPEN ACCESS

Cyclin-dependent kinase (CDK) inhibitors for hormone receptor-positive advanced breast cancer

Cochrane Database of Systematic Reviews (2018) 2018(1)
DOI: 10.1002/14651858.CD012919
3Citations
Citations of this article
53Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the effects of cyclin-dependent kinase (CDK) 4/6 inhibitors in the treatment of patients with hormone receptor-positive advanced breast cancer.

Cite

CITATION STYLE

APA

Syn, N. L. X., Wee, I., Wong, A. L. A., Goh, R. M., Ow, S. G. W., Lambertini, M., & Lee, S. C. (2018). Cyclin-dependent kinase (CDK) inhibitors for hormone receptor-positive advanced breast cancer. Cochrane Database of Systematic Reviews, 2018(1). https://doi.org/10.1002/14651858.CD012919

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free